Signature Equity Partners’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.72K Buy
45
+9
+25% +$1.72K ﹤0.01% 819
2026
Q1
$6.6K Buy
36
+32
+800% +$5.9K ﹤0.01% 902
2025
Q4
$704 Buy
+4
New +$653 ﹤0.01% 1477

Other funds holding BIIB

Signature Equity Partners's BIIB Position: Q2 2026 in Review

Signature Equity Partners increased its Biogen (BIIB) stake by 25% in Q2 2026, buying an estimated $1.72K and bringing the position to 45 shares worth $9.72K. The position accounts for ﹤0.01% of the portfolio, ranked #819.

Signature Equity Partners first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Signature Equity Partners held 45 shares of Biogen worth $9.72K as of Q2 2026.
  • Signature Equity Partners bought 9 Biogen shares in Q2 2026, an estimated $1.72K.
  • Biogen made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #819 holding.
  • Signature Equity Partners first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.